Lupus News

Patients with multiple diseases that share immunologic pathways may benefit from therapies that target those shared pathways, but additional studies are needed in this area, according to a presenter at the 2023 AWIR annual conference.

Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus that may play a larger role in the future, according to a presenter at the 2023 AWIR annual conference.

AUSTIN, Texas — Although reproductive health represents a unique challenge in patients with lupus, success is possible with careful planning and consideration, said a presenter at the 2023 Rheumatology Nurses Society annual conference.

Patients with systemic lupus erythematosus demonstrate a higher risk for ischemia heart disease, with the biggest danger manifesting 6 to 9 years after diagnosis, according to data published in BMC Rheumatology.

Increasing clinical trial awareness and support among Black patients with lupus, with the cooperation of nurses, will require improving trust and strong relationships, noted a speaker at the 2023 ACR Clinical Trials Summit.

Despite the fact that Black individuals routinely demonstrate the highest prevalence rates for lupus — with frequencies two to three times that of white individuals — they still account for just 14% of clinical trial participants.

Although testing for antinuclear antibodies is widely viewed as an effective screening tool for lupus and other autoimmune diseases, many rheumatologists fear that excessive ANA testing does more harm than good.

Although the annual retinopathy screening rate in patients with lupus receiving hydroxychloroquine has increased from 3.5% in 2006 to 22.5% in 2019, more work is needed to raise awareness, according to data from a South Korean study.

Patients with childhood systemic lupus erythematosus who receive care that closely adheres to quality metrics demonstrate better outcomes, according to data published in Arthritis Care & Research.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.